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Polycystic ovary syndrome represents 80% of anovulatory infertility cases. Treatment initially includes
preconception guidelines, such as lifestyle changes (weight loss), folic acid therapy to prevent the risk of fetal
neural tube defects and halting the consumption of tobacco and alcohol. The first-line pharmacological
treatment for inducing ovulation consists of a clomiphene citrate treatment for timed intercourse. The second-
line pharmacological treatment includes the administration of exogenous gonadotropins or laparoscopic
ovarian surgery (ovarian drilling). Ovulation induction using clomiphene citrate or gonadotropins is effective
with cumulative live birth rates of approximately 70%. Ovarian drilling should be performed when laparoscopy
is indicated; this procedure is typically effective in approximately 50% of cases. Finally, a high-complexity
reproduction treatment (in vitro fertilization or intracytoplasmic sperm injection) is the third-line treatment and
is recommended when the previous interventions fail. This option is also the first choice in cases of bilateral
tubal occlusion or semen alterations that impair the occurrence of natural pregnancy. Evidence for the routine
use of metformin in infertility treatment of anovulatory women with polycystic ovary syndrome is not available.
Aromatase inhibitors are promising and longer term studies are necessary to prove their safety.
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’ INTRODUCTION
Polycystic ovary syndrome (PCOS) is an endocrine and
reproductive disorder with a prevalence ranging from 5% (1)
to 13% (2) in women of reproductive age. PCOS is the
primary cause of hyperandrogenism and oligo-anovulation
at the reproductive age and is often associated with infertility
(3) and clinical and metabolic disorders (4).
The prevalence of infertility in women with PCOS varies
between 70 and 80%. According to the American Society for
Reproductive Medicine, the evaluation of infertility in
women with PCOS or other causes of subfertility should
start after six months of attempting pregnancy without
success if the couple has regular sexual intercourse (2 to
3 times/week) without using contraceptive methods (7). To
optimize the efficacy of the treatment of infertile women with
PCOS, evaluations of tubal patency (hysterosalpingography
or laparoscopy with chromotubation) and semen analysis
(spermogram) are mandatory before deciding on treatment.
However, tubal patency evaluation may not be necessary
prior to initiating clomiphene citrate (CC) treatment.
Notably, if a patient is resistant to this drug and/or requires
the use of gonadotropins and/or presents with other causes
of infertility, a tubal patency evaluation becomes mandatory
prior to initiating the therapeutic treatment of infertility (8).
The principle infertility treatment initially includes pre-
conception guidelines and the use of drugs to induce mono-
or bifollicular ovulation. Other therapeutic modalities may
also be employed, such as exogenous gonadotropins or
laparoscopic ovarian drilling, which are considered to be
second-line treatments, or in vitro fertilization (IVF), which is
a third-line treatment (9). Thus, the choice of the most
appropriate treatment depends on the patient’s age, presence
of other factors associated with infertility, experience and
duration of previous treatments and the level of anxiety of
the couple.
Non-pharmacological measures
Change in lifestyle and counseling of pregnancy
complications in women with PCOS. Lifestyle change is
considered the first-line treatment for infertility in obese
women with PCOS. Preconception counseling, administering
folic acid to reduce the risk of fetal neural tube defects,
encouragement of physical activity and identification of risk
factors, such as obesity, tobacco use and alcohol consump-
tion, should be performed. A 5 to 10% loss in body weightDOI: 10.6061/clinics/2015(11)09
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over a period of six months regardless of body mass index
may be associated with improvement in central obesity,
hyperandrogenism and ovulation rate (9). However, no
studies with the proper methodology have assessed the live
birth rate, which is the primary reproductive outcome (10).
Obese women with PCOS may have an increased risk of
congenital anomalies (heart and neural tube defects),
gestational diabetes mellitus [odds ratio (OR) 2.94; 95%
confidence interval (CI): 1.70-5.08], hypertensive disorders
during pregnancy (OR 3.67; 95% CI: 1.98-6.81) [mainly
preeclampsia (OR 3.47; 95% CI: 1.95-6.17)], miscarriages,
preterm births (OR 1.75; 95% CI: 1.16-2.62), the need for
intensive unit care (OR 2.31; 95% CI: 1.25-4.26), increased
perinatal mortality (OR 3.07; 95% CI: 1.03-9.21) (11,12) and
Caesarean delivery (OR 1.74; 95% CI: 1.38-2.11) (12). The risk
for preterm births and preeclampsia appears to be associated
with maternal hyperandrogenism (13).
In addition to improving reproductive and metabolic
factors, the reduction in body weight may be associated with
reduced incidence of complications during pregnancy and
the neonatal period. In this context, lifestyle change should
be the first choice for weight loss because medications to
reduce weight could have side effects and bariatric surgery
may be associated with preterm and small for gestational age
births (14).
Pharmacological measures
First-line treatment: Clomiphene citrate. In anovulatory
women with PCOS defined according to the Rotterdam
consensus (includes all phenotypes except the one defined by
the association of hyperandrogenism with ultrasound (US)
findings), CC treatment is the first choice for ovulation induction
(9,15). This drug is an estrogen receptor modulator (it can act as
an estrogen agonist or antagonist) and its mechanism of action
is controversial but can be explained as follows. In physiological
menstrual cycles, low levels of estrogen promote negative
feedback in the hypothalamus and pituitary gland and inhibit
the endogenous secretion of gonadotropin during the early
follicular phase. When CC is administered in this phase of the
cycle, it competes with estrogen for its receptors in the
hypothalamus and pituitary, which will block the negative
feedback mechanism. Consequently, increased levels of endo-
genous gonadotropins are released and the dominant follicle is
recruited (follicle that has the highest number of follicle-
stimulating hormone (FSH) receptors) between the sixth and
ninth day of the menstrual cycle (16).
The advantages of CC use are low cost, oral administration,
few side effects (flushing, headache, visual disturbances and
abdominal discomfort), the induction of monofollicular devel-
opment in most cases (16) and a low rate of multiple gestations
(2 to 13%) (17). The initial dose is 50 mg/day for five days
(starting between the second and fifth day of the menstrual
cycle) and may be increased to 150 mg/day (17,18); however,
doses greater than 100 mg/day usually do not offer additional
benefits (may be useful in obese women) (18). The ovulation
rate may reach 75 to 80% (19) with a conception rate of 22% per
cycle (20) and a cumulative pregnancy rate between 60 and 70%
in six cycles (9). There is no evidence that the administration of
human chorionic gonadotropin (hCG) in the mid-cycle increases
ovulation rates (OR 0.99; 95% CI: 0.36-2.77) or clinical pregnancy
(OR 1.02; 95% CI: 0.56-1.89) (21,22). CC treatment should be
limited to six ovulatory cycles and US monitoring is not
mandatory (it is recommended only in the first ovulatory cycle
to adjust the dose based on the ovarian follicular growth and
development and for endometrial assessment) (17,18). Addi-
tional cycles of ovulation induction with CC (maximum of
twelve cycles) may be individually evaluated based on the cost-
effectiveness and age of women and after discussion with the
couple (9). The incidence of ovarian hyperstimulation syndrome
(OHSS; increased capillary permeability with consequent third-
space fluid sequestration and hemoconcentration) associated
with the use of CC is low, approximately 1 to 6% (17,23).
Approximately 15% of women with PCOS do not respond
to the maximum dose of CC and are considered resistant to
this medication. Due to the anti-estrogenic effect of this drug,
endometrial proliferation may be inappropriate, which
decreases the chance of embryo implantation. Moreover, this
effect can also change the cervical mucus characteristics with a
consequent reduction in sperm penetration (17,23). If the
patient does not ovulate after the use of CC, gonadotropins for
timed intercourse or ovarian drilling are the next steps to
manage anovulatory infertile women with PCOS (9).
In practice, CC treatment can initiate the menstrual cycle as
early as the second day. Classically, this drug treatment has
been initiated between the third and fifth day of the menstrual
cycle and maintained for 5 days. Ovulation typically occurs
seven days after the last CC tablet is taken. Seven days after
the probable date of ovulation, follicular rupture can be
confirmed by progesterone levels greater than 3 ng/dL
(evaluated only at the beginning of the treatment to verify
the response to CC when US is unavailable) and pregnancy
can be confirmed by measuring the blood beta fraction of
human chorionic gonadotropin (bhCG) 7 days after the
progesterone measurement. The couple should maintain their
usual frequency of sexual intercourse, including during the
fertile period. This protocol is ideal for primary healthcare
centers with limited subsidiary resources.
Where US is available, CC treatment should be initiated
between the third and fifth day of the menstrual cycle and the
couple should abstain from intercourse (this is not a
mandatory measure) until the tenth day of the cycle (when
the presence of dominant follicles with a mean diameter of
10 mm or more is assessed via US). Sexual activity is allowed if
the patient presents with monofollicular or bifollicular devel-
opment. The goal of sexual abstinence until the tenth day of
the cycle is to minimize the risk for multiple gestations.
Couples with infrequent sexual intercourse may experience
some benefit from the use of kits for ovulation monitoring
(urinary luteinizing hormone excretion); however, this techni-
que can underestimate the fertile window. The evaluation of
cervical mucus throughout the menstrual cycle demonstrated
similar efficacy to urinary kits for monitoring the ovulation
and high rates of false positives in cycles are noted using the
hCG (24). Thus, this method has not been routinely used in
clinical practice, mainly when US is available.
Second-line treatment: Gonadotropins. The second-
line pharmacological treatment of infertility in anovulatory
women with PCOS includes the use of gonadotropins
[recombinant follicle-stimulating hormone (FSHr) or human
menopausal gonadotropin (HMG)] for timed intercourse or
intrauterine insemination (IUI) (9). Due to the higher cost of
this therapeutic modality, an evaluation of the tubal patency
is recommended prior to initiating the ovarian stimulation
with gonadotropins if this procedure was not performed
prior to initiating CC treatment. If the fallopian tube is opened
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and the sperm concentration is suitable for in vivo fertilization,
the ovarian stimulation begins with low doses of gonadotropins
(37.5 to 75 IU/day or every other day) to achieve monofollicular
growth and reduce the risk of complications (OHSS and
multiple gestation) (25). US monitoring of the follicular growth
(follicular diameter measurement) is mandatory in this case and
the endogenous secretion of gonadotropins does not need to be
inhibited with gonadotropin-releasing hormone analogues
(GnRH-a) during the timed intercourse cycles. The administra-
tion of hCG (used to simulate the endogenous peak of
luteinizing hormone for final oocyte maturation and ovulation
triggering) is unnecessary because it does not increase
the probability of conception during ovulation induction cycles
for timed intercourse (21). It is important to note that if
gonadotropin is chosen as the treatment option, the IUI has a
higher likelihood of successful pregnancy compared with timed
intercourse in patients with subfertility (26).
The IUI is performed with the same dose of gonadotropins
recommended for timed intercourse (combined or not with
clomiphene). However, for this treatment modality, the recom-
binant hCG is administered for final oocyte maturation when
the dominant follicle has a mean diameter of 17 to
18 mm via US examination and capacitated sperm can be
injected into the uterine cavity 36 hours later. Beta hCG is
measured 14 days later to confirm pregnancy (25).
Sperm capacitation must be evaluated to perform the low-
complexity treatment (semen evaluation after preparation to
estimate the number of sperm with progressive motility, which
includes those that theoretically have the ability to ascend
the female reproductive tract in vivo and fertilize the egg in
the fallopian tube). Thus, the semen is centrifuged and the
concentration of capacitated sperm recovered is measured as
follows: 410 million recovered motile sperms (any infertility
treatment is viable);45 million (IUI, in vitro fertilization (IVF) or
intra-cytoplasmic sperm injection (ICSI) may be performed);
between 1 and 5 million (IVF or ICSI may be performed); and
o1 million (only ICSI can be performed) (27,28). It is worth
noting that if the patient presents with bilateral tubal occlusion
in the initial assessment, sperm capacitation is only performed
to evaluate the possibility of performing IVF or ICSI (8).
The use of gonadotropins for timed intercourse is associated
with an ovulation rate of approximately 70%, a clinical
pregnancy rate of 20% per cycle and a multiple live birth rate
of 5.7% (9). Due to the cost of the treatment, the need for regular
monitoring of the follicular development via ultrasound and the
higher pregnancy rates with IUI, the use of gonadotropin is not
routine for timed intercourse. Instead, this medication is used in
IUI (26) or high-complexity treatments (IVF or ICSI) (9).
Second-line treatment: Laparoscopic ovarian surgery.
This therapeutic modality is also considered a second-line
treatment for the infertility of women with PCOS. However,
because it is an invasive method that requires general
anesthesia and has a higher cost and potential complications,
this technique should be used in cases of anovulatory women
with CC-resistant PCOS who require laparoscopy for another
reason (pelvic pain, adnexal mass, etc.). This technique can be
performed using monopolar electrocautery or laser techniques,
with both exhibiting a similar efficacy and the goal is between
4 and 10 punctures because a larger number may favor the
development of premature ovarian failure (25,29). The
mechanism of action of ovarian drilling in the treatment of
infertility in women with PCOS is suggested to be based on the
decreased secretion of androgens and consequent reduction of
peripheral aromatization of these compounds into estrone.
Furthermore, the follicular microenvironment becomes more
estrogenic, which facilitates follicular growth (30). Regarding
the efficacy of ovarian drilling, observational studies demon-
strated that the ovulation rate was between 54 and 76% in the
6 months after the procedure and 33 and 88% in the 12 months
after the procedure. During these periods, the spontaneous
pregnancy rate ranged between 28 and 56% and 54 and
70%, respectively (31).
If the patient does not present with ovulatory cycles at three
months after ovarian drilling, then the procedure should be
combined with CC treatment. The use of gonadotropins should
be considered after 6 months of anovulatory cycles following
the ovarian drilling procedure. Ovarian drilling should not be
indicated as a treatment for menstrual irregularity, metabolic
complications or hyperandrogenism in PCOS (29).
Ovarian drilling has some advantages compared with
gonadotropin treatment because it is associated with a lower
multiple gestation rate (OR 0.13; 95% CI: 0.03 to 0.52; p=0.004;
I(2)=0%; 5 trials; n=166) (29) and does not require US
monitoring of follicular development (9). However, the long-
term impact of ovarian drilling on the ovarian reserve/ovarian
function remains unknown (29).
Due to the high cost of the procedure, the need for
hospitalization, general anesthesia and higher complications
risks, ovarian drilling presents low cost effectiveness compared
with gonadotropin plus timed intercourse. Moreover, the lack of
standardization of the surgical technique and the absence of
studies that have evaluated the repercussions of long-term of
ovarian drilling demonstrate that this procedure should not be
routinely performed but should only be considered as second
line of therapy in women with PCOS who will be undergoing
laparoscopy for another reason (adnexal mass or pelvic pain, for
example). Additionally, ovarian drilling could be an alternative
before the assisted reproduction treatment (ART) in individuals
without financial conditions for the realization of ARTand those
who are resistant to CC.
Third-line treatment: in vitro fertilization. In vitro
fertilization represents the third-line treatment for infertility in
women with PCOS (9). However, if the initial assessment
demonstrates a bilateral tubal occlusion and/or concentration of
recovered motile sperm less than or equal to 5 million, this
treatment becomes the first option along with lifestyle changes.
The risk of OHSS is the main complication of the highly
complexity treatment in women with PCOS. Thus, to minimize
this side effect, ovarian stimulation should be initiated with low
doses of gonadotropins (100 to 150 IU of FSHr) and the pituitary
should be suppressed with a gonadotropin-releasing hormone
(GnRH) antagonist because this method is associated with a
reduced risk of OHSS compared with an agonist (29 randomized
control trials (RCTs); OR 0.43; 95% CI: 0.33 to 0.57) (32). If the
patient presents with clinical and ultrasound signs of OHSS, final
oocyte maturation should be performed with a GnRH agonist
and embryos should be frozen and transferred in a subsequent
cycle (33,34). Infertile women with PCOS may present with
better general oocyte and embryo quality rates; however, the
clinical pregnancy and live birth rates are similar to those
observed in normo-ovulatory women without PCOS (35).
Metformin
Although metformin is associated with better clinical
pregnancy rates (positive beta hCG) (pooled OR 2.31; 95%
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CI: 1.52 to 3.51; 8 trials; 707 women), there is no evidence of
better live birth rates (the main variable used to evaluate the
effectiveness of a treatment for infertility) when this drug is
used alone (pooled OR 1.80, 95% CI: 0.52 to 6.16; 3 trials;
115 women) or in combination with CC (pooled OR 1.16; 95%
CI: 0.85 to 1.56; 7 trials; 907 women) (36). From a reproduction
standpoint, there is also no benefit for its use in short (less than
four weeks) or long (more than four weeks) periods prior to
starting CC treatment in women with PCOS. Therefore, the use
of metformin should be restricted to the treatment of glucose
intolerance or type 2 diabetes in women with PCOS and
should not be used to induce ovulation (9,36).
However, in women with PCOS receiving low doses of
gonadotropins for timed intercourse, metformin administration
can double the clinical pregnancy rate (OR 2.25; 95%
CI: 1.50 to 3.38; po0.001; 7 trials) and the live birth rate (OR
1.94; 95% CI: 1.10 to 3.44; p=0.020; 2 trials). Moreover, this
practice can reduce the cancellation rate due to ovarian
hyperresponsiveness by approximately 60% (OR 0.41; 95%
CI: 0.24 to 0.72; p=0.002; 7 trials), the number of days of
stimulation (mean difference (MD)=-3.28; 95% CI: -6.23 to 0.32;
p=0.030; 6 trials) and the dose of gonadotropins (MD=-306.62;
95% CI: -500.02 to -113.22; p=0.002; 7 trials) in low-complexity
cycles. However, the use of metformin is not related to a
reduction in the multiple pregnancy rate (OR 0.32; 95% CI: 0.08
to 1.23; p=0.100; 3 trials), a change in the miscarriage rate (OR
0.47; 95% CI: 0.14 to 1.54; p=0.210; 5 trials) or OHSS (OR 0.56;
95% CI: 0.26 to 1.21; p=0.140; 5 trials). Notably, no conclusive
data are available on the appropriate dose and time (pre-
treatment or during gonadotropin treatment) for the use of
metformin during timed intercourse with gonadotropins (37).
For assisted reproduction cycles, metformin use prior to or
during ovarian stimulation with gonadotropins in IVF/ICSI
cycles is also not associated with better clinical pregnancy or
live birth rates; however, metformin may reduce the risk of
OHSS (38,39) and miscarriage and improve the implantation
rate because metformin may act directly on the endometrium
(39) and promote better reproductive outcomes (data not
confirmed) in women with PCOS (40). However, as previously
mentioned, the use of a GnRH antagonist combined with
ovarian stimulation with gonadotropins in women with PCOS
and the induction of final ovarian maturation with a GnRH
agonist with subsequent embryo cryopreservation are more
effective strategies to prevent OHSS regardless of metformin
use (33). Thus, the routine use of metformin in cycles of ovarian
stimulation for IVF in women with PCOS is not recommended
except in the presence of a disorder in glucose metabolism (9).
Aromatase inhibitors. Although aromatase inhibitors have
been used in women with PCOS as an alternative method to
avoid the anti-estrogenic effect of CC on the endometrium, these
compounds are not typically used in clinical practice to treat
infertility in these patients. Their mechanism of action is based
on reducing the peripheral conversion of androgens to estrogens
in ovarian granulosa cells by blocking aromatase. Consequently,
a decrease in estrogen serum levels and in its negative feedback
in the hypothalamus and pituitary gland is noted, resulting in
increased endogenous gonadotropin release (41).
The effectiveness of aromatase inhibitors in the treatment
of PCOS remains controversial. A meta-analysis investigated
78 studies on the use of these medications in the infertility
treatment of women with PCOS. Of these studies, 13 RCTs met
the inclusion criteria. Six studies compared the use of letrozole
versus CC and found that letrozole presented with a higher
ovulation rate/patient (OR 2.90; 95% CI: 1.72- 4.88; po0.0001);
however, no significant differences in the rate of ovulation per
cycle or better pregnancy, live birth, multiple pregnancy or
miscarriages rates were noted. Letrozole also did not obtain
better results regarding clinical pregnancy or live birth rates
compared with placebo or CC + metformin in women with
CC-resistant PCOS. The results of the comparison of the effects
of letrozole and anastrozole on ovulation and pregnancy rates
in women with CC-resistant PCOS are controversial (41).
In contrast, another recent meta-analysis reviewed
26 studies that evaluated the use of letrozole in women with
PCOS. The use of letrozole in cycles for timed intercourse was
associated with higher live birth (nine studies; OR 1.63; 95%
CI: 1.31 to 2.03; n=1783; I2=3%) and clinical pregnancy rates
(fourteen studies; OR 1.32; 95% CI: 1.09 to 1.60; n=2066;
I2=25%) compared with CC treatment; however, this evidence
was poor. Studies comparing the use of letrozole versus ovarian
drilling revealed no differences in live birth, clinical pregnancy
or OHSS rates. The administration of letrozole for 5 or 10 days
at a dose of 5 or 7.5 mg/day displayed similar clinical
pregnancy rates (42). A recent study found that the use of
letrozole was associated with higher live birth rates and
ovulation among 750 infertile women with polycystic ovary
syndrome compared with clomiphene (43).
From a practical standpoint, the use of aromatase inhibitors
may be an option before IVF/ICSI after counseling and the
consent of the couple in specific cases of women with CC-
resistant PCOSwithout other infertility factors and for whom the
high-complexity treatment is cost-prohibitive (41). The recom-
mended dose of letrozole is 5 to 10 mg/day for 5 to 10 days.
The principle infertility treatment includes lifestyle changes.
The first-line drug treatment to induce ovulation consists of CC
with timed intercourse. The second-line treatment consists of the
exogenous administration of gonadotropins or laparoscopic
ovarian surgery in cases where laparoscopy is indicated. The
third-line treatment consists of IVF/ICSI, which is indicated
when the previous interventions fail; this treatment can also be
the first choice in cases of bilateral tubal occlusion or semen
alterations that impair the occurrence of natural pregnancy.
There is no evidence for the routine use of metformin in
infertility treatment of anovulatory women with PCOS.
Aromatase inhibitors are promising, and long-term studies are
necessary to prove their safety.
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